10075662Scalable economic DNA synthesis by oligoseed amplification with novel DNA polymerase enzymesClosedCollaborative R&DInnovate UKEngineered DNA is an enabler for the UK's economic success (UK-Innovation-Strategy-2021). It is a mainstream component for cell and gene therapies, advanced diagnostics, and RNA vaccines. Hundreds of kilograms of DNA will soon be required globally each year, much more than current global capacity to supply it. The long-standing mainstream DNA production method, solid-phase phosphoramidite synthesis, is environmentally unsustainable and suffers from low accuracy & quality, limited DNA length & yield, and significant manufacturing delays. Today, reaching high DNA yields largely relies on manufacturing-level scale-up in bacteria or other cells, which is a costly manufacturing bottleneck. The UK Government prioritises an escalation in molecular therapeutics and advanced diagnostics development and manufacture, and to build resilience against future pandemics (Life-Sciences-Strategy-2021). Nunabio's unique technology addresses these needs as it promises to provide gram quantities of high-purity DNA feeding into these key applications. The project targets a scalable, commercially viable process and product. Nunabio will shorten DNA turnaround (12-16h vs up to 72h+), help each user save up to £1.4Mn/year, and remove 1.9Mn litres of harmful phosphoramidite reagents from industrial use by 2029\.